Kinki University
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Private
- Established
- 1943-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.kindai.ac.jp
Clinical Trials
8
Active:0
Completed:4
Trial Phases
3 Phases
Phase 1:2
Phase 2:2
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
4 (50.0%)Phase 1
2 (25.0%)Phase 2
2 (25.0%)Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis
Phase 2
- Conditions
- Lupus Nephritis
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Kinki University
- Target Recruit Count
- 20
- Registration Number
- NCT01226147
- Locations
- π―π΅
Kinki University Hospital, Osaka, Japan
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer
Phase 1
Completed
- Conditions
- Gastric Cancer
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Kinki University
- Target Recruit Count
- 9
- Registration Number
- NCT00845611
- Locations
- π―π΅
department of surgery, Kinki University, Osakasayama, Osaka, Japan
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer
Phase 1
Completed
- Conditions
- Esophageal Cancer
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Kinki University
- Target Recruit Count
- 7
- Registration Number
- NCT00753844
- Locations
- π―π΅
department of surgery, Kinki University, Osakasayama, Osaka, Japan
News
No news found